Apheresis Science Research Articles

Intravenous immunoglobulin therapy for COVID-19 ARDS

Intravenous immunoglobulin therapy for COVID-19 ARDS

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy (TMA), characterized by widespread intravascular thrombosis. Diagnosis of TTP is confirmed by a deficiency in ADAMTS13. However, given the urgency of prompt diagnosis and delayed turnaround time of ADAMTS13 assay in most labs, initial diagnosis is based on clinical acumen. Suspected TTP is empirically treated with plasma exchange (PLEX), which, while beneficial in TTP, may delay appropriate treatment for similar disorders. The PLASMIC score was developed by Bendapudi et al. (Lancet Hematology 2017) to utilize clinical signs and investigations to predict which patients had an ADAMTS13 score &lt; 10%, and therefore TTP, who require PLEX. Validation studies have shown a very high sensitivity (90-98%) and high specificity (46-92%), although these studies included an enriched population with available ADAMTS13 assay results (Jajosky et al. Transfusion and Apheresis Science, 2017, Li et al. Journal of Thrombosis and Hemostasis 2018). The purpose of this study is to validate the PLASMIC score using a Canadian population of suspected TTP regardless if ADAMTS13 was ordered, and compare it to clinical gestalt. This is a retrospective cohort study of all adults aged 18 years or older who presented or were transferred to any of the two apheresis centres in Alberta, Canada with a suspected diagnosis of TTP from January 1, 2008 - December 31, 2018. A confirmed diagnosis of TTP was defined as an ADAMTS13 level prior to PLEX &lt; 10%, or ADAMTS13 level between 10-20% if drawn after plasma infusion or PLEX. ADAMTS13 testing was done in accordance with the procedures at these institutions. The PLASMIC score was used to stratify patients into low (0-4), intermediate (5) and high (6-7) risk of TTP (Table 1). Descriptive analyses was performed to examine the proportion of patients with low-, intermediate-, and high-risk PLASMIC score who had ADAMTS13 testing done and who received PLEX. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of PLASMIC score were calculated. Two PLASMIC score cutoffs were used for the analysis, 1) high risk vs low to intermediate risk, and 2) intermediate to high risk vs low risk. Receiver operator curve (ROC) analysis was used to test the association between severe ADAMTS13 deficiency and the PLASMIC score. PLASMIC scores were also compared to clinical gestalt, defined as initiation of PLEX within 48 hours of presentation. The C statistic was calculated from the area under the ROC and compared using the Z-test. As some patients who may have died from TTP did not have ADAMTS13 level sent, sensitivity analysis was performed to assess the ROC curve for the PLASMIC score in detecting both definite and probable TTP. A P-value of &lt;0.05 was considered statistically significant. Of the 162 cases of suspected TTP, 61 (38%) had severe ADAMTS13 &lt;10%. ADAMTS13 was sent prior to plasma exchange in 103 (64%) cases and shortly after PLEX initiation in 15 (9%). Using a high-risk PLASMIC score cut-off (6-7) vs low to intermediate-risk score (0-5), the sensitivity was 83.6%, specificity 67.3%, PPV 60.7% and NPV 87.2%. In contrast, using a cut-off of medium to high-risk PLASMIC score (5-7) vs low-risk score (0-4), the sensitivity improved to 96.7%, whereas the specificity was reduced to 30.7% (PPV 45.7% and NPV 93.9%). The C-statistics were 0.75 (95% CI 0.69-0.82) and 0.64 (95% CI 0.59-0.69) using the high PLASMIC score and medium-high PLASMIC score cut-offs, respectively (Figure 1). In contrast to PLASMIC score-based risk stratification, clinical gestalt has a comparable sensitivity of 83.6%, but a much lower specificity of 38.9%. There was very low correlation between PLASMIC score and clinical gestalt (kappa 0.0883 (95% CI -0.03-0.21). In our cohort, a high-risk PLASMIC score successfully predicted patients with severe ADAMTS13 deficiency in a Canadian TMA population, with similar sensitivity and improved specificity compared to clinical gestalt. Integration of this scoring system into institutional clinical pathways should be considered to supplement clinician judgment and reduce costs. Disclosures No relevant conflicts of interest to declare.

A Comparison of Hematologic Parameters in Patients with Sickle Cell Disease Undergoing Red Cell Exchange Using Terumo BCT Spectra Optia and COBE Spectra Apheresis Systems

Introduction:Therapeutic red blood cell exchange (RBCX) is a process by which diseased red cells are replaced by healthy donor red blood cells. In patients with sickle cell disease, RBCX has been used to treat acute stroke, severe acute chest syndrome, multiorgan failure, priapism and splenic sequestration. It is also being used more commonly in the prevention of vaso-occlusive pain crises and for stroke prophylaxis for patients considered to be at high risk of stroke based on abnormal transcranial Doppler flow rates. In May 2014, we transitioned from the COBE Spectra apheresis system (Terumo BCT) to the next-generation Spectra Optia apheresis system (Terumo BCT) for all red cell exchange transfusions performed on our patients with sickle cell disease. A previous small study (n = 33 RBCX transfusions) compared the two instruments (Caridian BCT) and showed no difference between exchange volumes, processing time, pre and post-exchange hematocrit and HbS levels (Perseghin et al. Transfusion and Apheresis Science, 2013). However, other clinical parameters such as changes in white blood cell count and platelet counts were not examined. In order to determine if there were any differences in hematologic parameters between the 2 apheresis instruments, we measured the differences between pre and post-exchange HbS levels, white blood cell count (WBC), hematocrit (Hct), and platelet counts for all of our adult patients who underwent RBCX transfusions on both instruments.Methods:This was a single institution, retrospective chart review of all adult patients with sickle cell disease (HbSS n=17, HbS/β0 thalassemia n = 1, HbSC n =1) who underwent routine, monthly RBCX at Children's Hospital and Research Center Oakland between November 2013 and February 2015. Indications for RBCX included a risk of stroke or a history of stroke, acute chest syndrome, or renal failure. All patients received RBCX transfusions on the COBE Spectra prior to May 2014 and were then transitioned to Spectra Optia in May 2014. Pre and post-exchange transfusion HbS levels, WBC, Hct, and platelet counts were measured for each procedure. All exchange transfusions were non-emergent and well tolerated. Statistical analyses using the student's t test and rank sum test were performed with Stata 14.0 software (College Station, Texas).Results:A total of 19 adult patients (mean average age 25 years old) underwent 153 red blood cell exchange transfusions (Spectra Optia n =87, COBE Spectra n = 66). There was a small increase in mean hematocrit percentage for both instruments (28.33 + 4.3 % to 29 + 3.06 % and 28.16 + 4.29% to 29.2 + 3.04% on the Spectra Optia and COBE Spectra, respectively). All other post-RBCX parameters decreased. The mean changes are shown in Table I. The HbS percent decreased from a combined mean of 39.86 + 12.11 % to 20.26 + 8.43 % for both instruments. The WBC decreased from a combined mean of 12.72 + 3.13 x 1000/ mm3 to 8.67 + 2.15 x 1000/ mm3. The platelet count decreased from a combined mean of 368.82 + 125.75 x 1000/ mm3 to 191.01 + 62.78 x 1000/ mm3. The mean parameter values for each patient correlated with the mean changes for each instrument based on statistical analysis using both the student's t test and rank sum test.Conclusions:The starting hematologic values were similar between the two instruments. There was no statistical difference between the raw pre and post-RBCX HbS, Hct, WBC, or platelet values or the mean changes in these parameters between the COBE Spectra and Spectra Optia instruments. There was also no statistical difference in the mean changes between the pre and post RBCX hematologic parameters amongst the 19 patients. Both instruments allowed for effective reduction in HbS percentage with comparable decreases in WBC and platelet counts while maintaining adequate hematocrit values for all 19 adult patients with sickle cell disease.Table 1Mean changes between Pre-RBCX and Post-RBCX.InstrumentChange in % HbSChange in WBC x1000/mm3Change in % HctChange in platelet count x1000/mm3Spectra OptiaN84878785Mean-20.28-4.010.67-172.44SD7.022.552.8676.98COBE SpectraN66666666Mean-19.18-4.121.09-178.02SD7.892.262.5781.02p-value0.370.780.340.67There are 3 missing values for HbS and 2 missing values for platelet count for Spectra Optia. SD = standard deviation, WBC = white blood cell count, Hct = hematocrit DisclosuresNo relevant conflicts of interest to declare.

World Apheresis Association President 2014–2016: Paolo Perseghin, MD

Dear Colleagues: It’s an honour for me to chair our active society. As the incoming WAA president for the period 20142016, first of all I would like to thank the previous whole WAA board and namely president Prof Hiroshi Tsuda and past-president Dr. Robert Weinstein for their valuable work. We all are all indebted to Prof Gail Rock for her extraordinary commitment as Editor-in-chief of the WAA official journal, Transfusion and Apheresis Science.

Granulocyte transfusions

Neutrophils play an essential role in the defense of the body against bacterial and fungal infections. Disorders of their number or function significantly increase the risk of life-threatening infection. In spite of the development of growth factors, new broad spectrum antibiotics and antifungal drugs against nearly all known pathogens, severe neutropenia associated with bacterial or invasive fungal infections remains a major cause of morbidity and mortality in patients undergoing aggressive cancer chemotherapy or hematopoietic stem cell transplantation. Lately, an interest about granulocyte transfusions was renewed, what is a logical approach in the management of patients with prolonged 'reversible' severe neutropenia and severe infection, which is not controlled with appropriate antimicrobial and supportive treatment, including recombinant hematopoietic growth factors. It was a consequence of advances in the field of apheresis science, use of sedimenting agents and especially advances in mobilization of granulocytes to the peripheral blood. It became now possible to collect large numbers of neutrophils. Therefore, the clinical use of granulocyte transfusions, as a potential life saving treatment option in patients with severe neutropenia and uncontrolled infection in spite of appropriate antimicrobial therapy should be considered, with regard to possible benefits and risks (Ref. 74).

The clinical trials section

In this issue of Transfusion and Apheresis Science we are introducing a new section which will address clinical trials. Dr. Ramlow from Rostock, Germany has agreed to take on the responsibility of Editor of this section. The purpose of this section will be to share information concerning proposed, ongoing or completed clinical trials with an international audience. We encourage our readers to let Dr. Ramlow know of any trials and/or provide their comments on such. He can be reached at:

What’s happening: Scotblood 2005: The donor, the product, the patient: How are we shaping up for the 21st century?

This year the annual meeting of the Scottish National Blood Transfusion Service (SNBTS), SCOTBLOOD, a conference organised and run by members of the SNBTS staff, was held at Stirling University on June 3 and 4. I was fortunate to attend this meeting with the aim of reporting back the main theme of this meeting to Transfusion and Apheresis Science, in collaboration with my good friend Hagop Bessos. The major theme of the meeting was based on the principles of quality, safety, and efficacy entitled ‘‘the donor (provider), the product, and the patient (the 3 P’s): how are we shaping up for the 21st century’’? It included several leading edge presentations, summaries of which are presented in this meeting report (see below). First however, the meeting was opened by Keith Thompson, SNBTS National Director, who alluded to the challenges of his first year in the post. He defended the SNBTS record on viral

Cord Blood Processing by Using a Standard Manual Technique and Automated Closed System "Sepax" (Kit CS-530)

Stem Cells and DevelopmentVol. 14, No. 1 CorrespondenceCord Blood Processing by Using a Standard Manual Technique and Automated Closed System "Sepax" (Kit CS-530)Bernard Dazey, Pascale Duchez, Catherine Letellier, Gerard Vezon, and Dr. Zoran IvanovicBernard DazeySearch for more papers by this author, Pascale DuchezSearch for more papers by this author, Catherine LetellierSearch for more papers by this author, Gerard VezonSearch for more papers by this author, and Dr. Zoran IvanovicSearch for more papers by this authorPublished Online:22 Feb 2005https://doi.org/10.1089/scd.2005.14.6AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byDiscarded plasma obtained after cord blood volume reduction as an alternative for fetal calf serum in mesenchymal stromal cells cultures6 August 2020 | Transfusion, Vol. 3Umbilical cord stem cells: Background, processing and applicationsTissue and Cell, Vol. 65Automated thawing increases recovery of colony-forming units from banked cord blood unit grafts11 October 2018 | Transfusion, Vol. 58, No. 12Cord Blood Graft Thawing14 October 2017Comparison of human umbilical cord blood processing with or without hydroxyethyl starch23 August 2017 | Transfusion, Vol. 57, No. 11Cord blood collection and processing with hydroxyethyl starch or non–hydroxyethyl starchCytotherapy, Vol. 18, No. 5Cell BankingCurrent thawing and infusion practice of cryopreserved cord blood: the impact on graft quality, recipient safety, and transplantation outcomes4 June 2014 | Transfusion, Vol. 54, No. 11A Novel Procedure to Improve Functional Preservation of Hematopoietic Stem and Progenitor Cells in Cord Blood Stored at +4°C Before Cryopreservation Jean Chevaleyre, Laura Rodriguez, Pascale Duchez, Marie Plainfossé, Bernard Dazey, Véronique Lapostolle, Marija Vlaski, Philippe Brunet de la Grange, Bruno Delorme, and Zoran Ivanovic7 April 2014 | Stem Cells and Development, Vol. 23, No. 15Cord blood banking activity in Iran National Cord Blood Bank: A two years experienceTransfusion and Apheresis Science, Vol. 50, No. 1Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cellsJournal of Translational Medicine, Vol. 12, No. 1Nutrient Regulation by Continuous Feeding Removes Limitations on Cell Yield in the Large-Scale Expansion of Mammalian Cell Spheroids18 October 2013 | PLoS ONE, Vol. 8, No. 10Cryopreservation of hematopoietic stem and progenitor cells amplified ex vivo from cord blood CD34+ cells11 December 2012 | Transfusion, Vol. 53, No. 9Functional Stability (at +4°C) of Hematopoietic Stem and Progenitor Cells Amplified Ex Vivo from Cord Blood CD34 + Cells1 August 2013 | Cell Transplantation, Vol. 22, No. 8Potential Application of Cord Blood-Derived Stromal Cells in Cellular Therapy and Regenerative MedicineJournal of Blood Transfusion, Vol. 2012Definitive Setup of Clinical Scale Procedure for Ex Vivo Expansion of Cord Blood Hematopoietic Cells for Transplantation1 November 2012 | Cell Transplantation, Vol. 21, No. 11Human Umbilical Cord Blood-Derived Very-Small-Embryonic-Like Stem Cells with Maximum Regenerative Potential? Zoran Ivanovic15 March 2012 | Stem Cells and Development, Vol. 21, No. 14Analysis of 120 pediatric patients with nonmalignant disorders transplanted using unrelated plasma-depleted or -reduced cord blood21 November 2011 | Transfusion, Vol. 52, No. 6Processing of hematopoietic stem cells from peripheral blood before cryopreservation: use of a closed automated system20 May 2011 | Transfusion, Vol. 51, No. 12Cord blood banking and transplantation20 October 2011 | ISBT Science Series, Vol. 6, No. 2Cell recovery comparison between plasma depletion/reduction- and red cell reduction-processing of umbilical cord bloodCytotherapy, Vol. 13, No. 9Clinical-Scale Cultures of Cord Blood CD34 + Cells to Amplify Committed Progenitors and Maintain Stem Cell Activity1 October 2011 | Cell Transplantation, Vol. 20, No. 9Cord (placental) blood storage: extent and functional aspects6 September 2011 | Transfusion, Vol. 51, No. 9High recovery of mesenchymal progenitor cells with non-density gradient separation of human bone marrowCytotherapy, Vol. 12, No. 5Expansion ex vivo des cellules hematopoiétiques : concept et utilité cliniqueTransfusion Clinique et Biologique, Vol. 16, No. 5-6A new automatic device for routine cord blood banking: critical analysis of different volume reduction methodologiesCytotherapy, Vol. 11, No. 8A clinical study on the feasibility of autologous cord blood transfusion for anemia of prematurityTransfusion, Vol. 48, No. 8Good Manufacturing Practice-Compliant Expansion of Marrow-Derived Stem and Progenitor Cells for Cell Therapy22 June 2017 | Cell Transplantation, Vol. 16, No. 7 Volume 14Issue 1Feb 2005 InformationCopyright 2005, Mary Ann Liebert, Inc.To cite this article:Bernard Dazey, Pascale Duchez, Catherine Letellier, Gerard Vezon, and Dr. Zoran Ivanovic.Cord Blood Processing by Using a Standard Manual Technique and Automated Closed System "Sepax" (Kit CS-530).Stem Cells and Development.Feb 2005.6-10.http://doi.org/10.1089/scd.2005.14.6Published in Volume: 14 Issue 1: February 22, 2005PDF download

Erratum to ?Rare illness, a case of Bullous Pemphigus: the benefits of apheresis? 6Transfusion and Apheresis Science 30 (2003) 73?759

The publisher regrets that an error occurred in the listing of the corresponding author of the above paper. G. Rock did not contribute to the paper. The correct author details are listed below: Armando Fiorilla*, Vincenzo Manenti, Angelo Gugliotta Servizio di Medicina Trasfusionale, Ospedale Maggiore, Modica, Ausl N7, Ragusa, Sicilia, Italia

Chronic Graft-Versus-Host Disease

Journal of Hematotherapy & Stem Cell ResearchVol. 9, No. 3 ReviewsChronic Graft-Versus-Host DiseaseJeffrey Margolis and Georgia VogelsangJeffrey MargolisSearch for more papers by this author and Georgia VogelsangSearch for more papers by this authorPublished Online:9 Jul 2004https://doi.org/10.1089/15258160050079443AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byPhysical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) GroupHematology/Oncology and Stem Cell Therapy, Vol. 12, No. 3The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD)Transfusion and Apheresis Science, Vol. 36, No. 1Clinical Spectrum and Therapeutic Approaches to Chronic Graft-vs.-Host Disease9 April 2013Enfermedad injerto contra huésped en el trasplante hematopoyéticoPiel, Vol. 19, No. 8T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantationTransplantation, Vol. 76, No. 12Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC1 October 2003 | Bone Marrow Transplantation, Vol. 32, No. 8Pathogenesis and Treatment of Graft-Versus-Host Disease After Bone Marrow TransplantAnnual Review of Medicine, Vol. 54, No. 1Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation F. Baron and Y. Beguin9 July 2004 | Journal of Hematotherapy & Stem Cell Research, Vol. 11, No. 2Nonmyeloablative Stem Cell Transplantation with CD8-Depleted or CD34-Selected Peripheral Blood Stem Cells Frédéric Baron, Etienne Baudoux, Pascale Frère, Soraya Tourqui, Nicole Schaaf-Lafontaine, Roland Greimers, Christian Herens, Georges Fillet, and Yves Beguin9 July 2004 | Journal of Hematotherapy & Stem Cell Research, Vol. 11, No. 2Chronic immune activation and inflammation in the pathogenesis of aids and cancerRetrospective Comparison of CD34-selected Allogeneic Peripheral Blood Stem Cell Transplantation Followed by CD8-depleted Donor Lymphocyte Infusions with Unmanipulated Bone Marrow Transplantation4 September 2013 | Hematology, Vol. 7, No. 3Stem Cell Transplantation: Supportive Care and Long-Term ComplicationsHematology, Vol. 2002, No. 1Severe Hematopoietic Alterations In Vitro, in Bone Marrow Transplant Recipients Who Develop Graft-Versus-Host Disease Guadalupe Martínez-Jaramillo, Enrique Gómez-Morales, Elizabeth Sánchez-Valle, and Hector Mayani9 July 2004 | Journal of Hematotherapy & Stem Cell Research, Vol. 10, No. 3 Volume 9Issue 3Jun 2000 To cite this article:Jeffrey Margolis and Georgia Vogelsang.Chronic Graft-Versus-Host Disease.Journal of Hematotherapy & Stem Cell Research.Jun 2000.339-346.http://doi.org/10.1089/15258160050079443Published in Volume: 9 Issue 3: July 9, 2004PDF download

Plasmapheresis in heparin-induced thrombocytopenia and thrombosis.

HomeStrokeVol. 21, No. 8Plasmapheresis in heparin-induced thrombocytopenia and thrombosis. Free AccessAbstractPDF/EPUBAboutView PDFSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessAbstractPDF/EPUBPlasmapheresis in heparin-induced thrombocytopenia and thrombosis. L Manzano, M Yebra, J A Vargas, L Barbolla and M Alvarez-Mon L ManzanoL Manzano Search for more papers by this author , M YebraM Yebra Search for more papers by this author , J A VargasJ A Vargas Search for more papers by this author , L BarbollaL Barbolla Search for more papers by this author and M Alvarez-MonM Alvarez-Mon Search for more papers by this author Originally published5 Apr 2018https://doi.org/10.1161/str.21.8.1236bStroke. 1990;21:1236"Plasmapheresis in heparin-induced thrombocytopenia and thrombosis.." Stroke, 21(8), p. 1236 Previous Back to top Next FiguresReferencesRelatedDetailsCited By Grazioli A, Athale J, Tanaka K, Madathil R, Rabin J, Kaczorowski D and Mazzeffi M (2020) Perioperative Applications of Therapeutic Plasma Exchange in Cardiac Surgery: A Narrative Review, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2020.01.054, 34:12, (3429-3443), Online publication date: 1-Dec-2020. Jones C, Pechauer S, Curtis B, Bougie D, Aster R and Padmanabhan A (2018) Normal plasma IgG inhibits HIT antibody–mediated platelet activation: implications for therapeutic plasma exchange, Blood, 10.1182/blood-2017-08-803031, 131:6, (703-706), Online publication date: 8-Feb-2018. Karafin M, Sachais B, Connelly-Smith L, Field J, Linenberger M and Padmanabhan A (2015) NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology-oncology, Journal of Clinical Apheresis, 10.1002/jca.21400, 31:1, (38-47), Online publication date: 1-Feb-2016. Schell A, Petras M, Szczepiorkowski Z and Ornstein D (2013) Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy, Transfusion and Apheresis Science, 10.1016/j.transci.2013.01.007, 49:2, (185-188), Online publication date: 1-Oct-2013. Jaben E, Torloni A, Pruthi R and Winters J (2011) Use of plasma exchange in patients with heparin-induced thrombocytopenia: A report of two cases and a review of the literature, Journal of Clinical Apheresis, 10.1002/jca.20289, 26:4, (219-224), . Greinacher A and Warkentin T (2007) Treatment of Heparin-Induced ­Thrombocytopenia: An Overview Heparin-Induced Thrombocytopenia, 10.3109/9781420045093.012, (283-318), Online publication date: 1-Jun-2007. Poullin P, Pietri P and LefÈvre P (2001) HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS: SUCCESSFUL THREATMENT WITH PLASMA EXCHANGE, British Journal of Haematology, 10.1046/j.1365-2141.1998.0847a.x, 102:2, (629-630), Online publication date: 1-Jul-1998. Poullin P, Pietri P and Lefèvre P (1998) Thrombopénie induite par l'héparine: régression rapide de la thrombopénie et de la thrombose après échange plasmatique. À propos d'un cas, La Revue de Médecine Interne, 10.1016/S0248-8663(98)80386-X, 19:11, (819-822), Online publication date: 1-Nov-1998. August 1990Vol 21, Issue 8 Advertisement Article InformationMetrics Copyright © 1990 by American Heart Associationhttps://doi.org/10.1161/str.21.8.1236bPMID: 2389306 Originally publishedApril 5, 2018 PDF download Advertisement

Fatty acid oxidation by human platelets and its stimulation by thrombin.

ARTICLESFatty acid oxidation by human platelets and its stimulation by thrombinR Donabedian, and Y NemersonR Donabedian, and Y NemersonPublished Online:01 Nov 1971https://doi.org/10.1152/ajplegacy.1971.221.5.1283MoreSectionsPDF (1001 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat Previous Back to Top Next Download PDF FiguresReferencesRelatedInformation Cited ByL-Carnitine as an additive in Tyrode's buffer during platelet storageBlood Coagulation & Fibrinolysis, Vol. 29, No. 7Extramitochondrial energy production in platelets16 April 2018 | Biology of the Cell, Vol. 110, No. 5Dissecting the metabolic pathways controlling platelet survival in vivo: are our platelets what they eat?8 August 2016 | Transfusion, Vol. 56, No. 8Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage21 April 2016 | Transfusion, Vol. 56Metabolic Plasticity in Resting and Thrombin Activated Platelets13 April 2015 | PLOS ONE, Vol. 10, No. 4L-carnitine effectively improves the metabolism and quality of platelet concentrates during storage18 November 2014 | Annals of Hematology, Vol. 94, No. 4Mitochondria: Biological roles in platelet physiology and pathologyThe International Journal of Biochemistry & Cell Biology, Vol. 50Glucose in platelet additive solutions: To add or not to add?Transfusion and Apheresis Science, Vol. 44, No. 3L-carnitine improves pH and decreases surface phosphatidylserine expression in extended stored apheresis platelets1 January 2004 | Journal of Clinical Apheresis, Vol. 19, No. 2l-carnitine decreases glycolysis in liquid-stored plateletsTransfusion, Vol. 40, No. 11Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responsesEuropean Journal of Pharmacology, Vol. 356, No. 2-3Fuel Choices by Human Platelets in Human PlasmaEuropean Journal of Biochemistry, Vol. 244, No. 1Carbohydrate metabolism in human platelets in a low glucose medium under aerobic conditionsBiochimica et Biophysica Acta (BBA) - General Subjects, Vol. 1291, No. 2Glutamine transport and enzymatic activities involved in glutaminolysis in human plateletsBiochimica et Biophysica Acta (BBA) - General Subjects, Vol. 1243, No. 1Effects of 2-tetradecylglycidic acid on rat platelet energy metabolism and aggregationBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, Vol. 1128, No. 2-3Adenine Nucleotides in Blood PlateletsEnergy Metabolism and Platelet ResponsesVox Sanguinis, Vol. 40 More from this issue > Volume 221Issue 5November 1971Pages 1283-1286 Copyright & PermissionsCopyright © 1971 by American Physiological Societyhttps://doi.org/10.1152/ajplegacy.1971.221.5.1283PubMed5124271History Published online 1 November 1971 Published in print 1 November 1971 Metrics

A microelectrode for measuring intracellular PO2.

A simple and reliable method of constructing an intracellular pH microelectrode is described. Antimony is used as the pH sensor. Antimony electrodes have been used in biological systems as early as 1927 (1). Since then several investigators have used different kinds of Sb electrodes. Roos and Boton (3) describe the latest methods of construction and application of pH sensitive micro-electrodes. In most cases the pH electrodes were fabricated by pulling glass capillaries filled with molten antimony and in a few cases by coating glass with antimony. The electrodes were of the open type.

Intracellular PO2: a limiting factor in cell respiration.

ARTICLESIntracellular PO2: a limiting factor in cell respirationWJ WhalenWJ WhalenPublished Online:01 Sep 1966https://doi.org/10.1152/ajplegacy.1966.211.3.862MoreSectionsPDF (1 MB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat Previous Back to Top Download PDF FiguresReferencesRelatedInformation Cited ByTissue oxygenation and capacity to deliver O2 do the two go together?Transfusion and Apheresis Science, Vol. 31, No. 1Individual Value of Brain Tissue Oxygen Pressure, Microvascular Oxygen Saturation, Cytochrome Redox Level, and Energy Metabolites in Detecting Critically Reduced Cerebral Energy State During Acute Changes in Global Cerebral PerfusionJournal of Neurosurgical Anesthesiology, Vol. 16, No. 3Skeletal muscle $$\dot V_{O_2 }$$ in rat and lemming: Effect of blood flow rateJournal of comparative physiology, Vol. 128, No. 2Factors Determining Total Body and Hind Limb Oxygen Consumption in Normal and Shocked DogsSauerstoffdruck, Sauerstoffverbrauch und Durchblutung in der Extremit�tenmuskulatur des wachen FroschesPfl�gers Archiv European Journal of Physiology, Vol. 321, No. 1Respiratory problems in pregnancyAmerican Journal of Obstetrics and Gynecology, Vol. 99, No. 7Intracellular Po 2 and Its Regulation in Resting Skeletal Muscle of the Guinea PigCirculation Research, Vol. 21, No. 3Glycogen and phosphocreatine synthesis in the isolated frog sartorius muscleLife Sciences, Vol. 6, No. 4 More from this issue > Volume 211Issue 3September 1966Pages 862-868 Copyright & PermissionsCopyright © 1966 by American Physiological Societyhttps://doi.org/10.1152/ajplegacy.1966.211.3.862PubMed5927916History Published online 1 September 1966 Published in print 1 September 1966 Metrics